ЛІТЕРАТУРА

  1. Волошин Н.Г., Григорьева Е.А. Лектины животного и растительного просхождения: роль в процессах морфогенеза // Журнал АМН України. — 2005. — 11, №2. — С. 223–237.
  2. Жебель В.М., Лозинський С.Е. Від гіпертрофії лівого шлуночка до гіпертензивного серця. Зміна парадигми // Український кардіологічний журнал. — 2011. — №6. — С. 88–93.
  3. Луцик А.Д., Детюк Е.С., Луцик М.Д. Лектины в гистохимии. — Львов: Вища школа, 1989. — 140 с.
  4. Abdulla J, Kоber L, Torp-Pedersen C. Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods? // Cardiovasc Drugs Ther. — 2004. — 18, №3. — Р. 219-24.
  5. Anand IS, Chandrashekhar Y, Ferrari R et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones // Br Heart J. — 1993. — 70, №4. — Р. 357-62.
  6. Andreassen AK, Nordoy I, Simonsen S et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation // Am J Cardiol. — 1998. — 81, №5. — Р. 604-8.
  7. Arason GJ. Lectins as defence molecules in vertebrates and invertebrates // Fish & Shellfish Immunology. — 1996. — 6, №4. — Р. 277-289.
  8. Arimoto T, Takeishi Y, Shiga R et al. Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure // J Card Fail. — 2005. — 11, №1. — Р. 56-60.
  9. Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy // Am J Cardiol. — 2004. — 94, №11. — Р. 1468-70.
  10. Assmus B, Schächinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) // Circulation. — 2002. — 106, №24. — P. 3009-17.
  11. Bahl VK, Malhotra OP, Kumar D et al. Noninvasive assessment of systolic and diastolic left ventricular function in patients with chronic severe anemia: a combined M-mode, two-dimensional, and Doppler echocardiographic study // Am Heart J. — 1992. — 124, №6. — Р. 1516-23.
  12. Barnes YC, Skelton TP, Stamenkovic I, Sgroi DC. Sialylation of the sialic acid binding lectin sialoadhesin regulates its ability to mediate cell adhesion // Blood. — 1999. — 93, №4. — Р. 1245-52.
  13. Barondes SH, Cooper DNW, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins // J. Biol. Chem. — 1994. — 269. — Р. 20807-20810.
  14. Bergler-Klein J, Klaar U, Heger M et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis // Circulation. — 2004. — 109, №19. — Р. 2302-8.
  15. Beitnes JO, Hopp E, Lunde K et al. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study // Heart. — 2009. — 95, №24. — P. 1983-9.
  16. Benedict CR, Shelton B, Johnstone DE et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators // Circulation. — 1996. — 94, №4. — Р. 690-7.
  17. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure // Annu Rev Pharmacol Toxicol. — 2005. — 45. — Р. 657-87.
  18. Brucks S, Little WC, Chao T et al. Relation of anemia to diastolic heart failure and the effect on outcome // Am J Cardiol. — 2004. — 93, №8. — Р. 1055-7.
  19. Caiola K, Cheng JW. Use of erythropoietin in heart failure management // Ann Pharmacother. — 2004. — 38, №12. — Р. 2145-9.
  20. Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study // Circulation. — 2003. — 108, №19. — Р. 2317-22.
  21. Chin BS, Blann AD, Gibbs CR et al. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure // Eur J Clin Invest. — 2003. — 33, №11. — Р. 941-8.
  22. Chin BS, Conway DS, Chung NA et al. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis // Blood Coagul Fibrinolysis. — 2003. — 14, №6. — Р. 515-21.
  23. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group // N Engl J Med. — 2000. — 343, №4. — Р. 246-53.
  24. Cooper DN. Galectinomics: finding themes in complexity // Biochim Biophys Acta. — 2002. — 1572, №2-3. — Р. 209-31.
  25. >Cowie MR, Jourdain P, Maisel A et al. Clinical applications of B-type natriuretic peptide (BNP) testing // Eur Heart J. — 2003. — 24, №19. — Р. 1710-8.
  26. Davis M, Espiner E, Richards G et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea // Lancet. — 1994. — 343, №8895. — Р. 440-4.
  27. de Boer RA, Pokharel S, Flesch M et al. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27 // J Mol Med (Berl). — 2004. — 82, №10. — Р. 678-87.
  28. de Groote P, Dagorn J, Soudan B et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure // J Am Coll Cardiol. — 2004. — 43, №9. — Р. 1584-9.
  29. Del Carlo CH, Pereira-Barretto AC, Cassaro-Strunz C et al. Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure // J Card Fail. — 2004. — 10, №1. — Р. 43-8.
  30. Dixon JA, Spinale FG. Myocardial remodeling: cellular and extracellular events and targets // Annu Rev Physiol. — 2011. — 73. — P. 47-68.
  31. Drazner MH, Rame JE, Marino EK et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study // J Am Coll Cardiol. — 2004. — 43, №12. — Р. 2207-15.
  32. Elola MT, Wolfenstein-Todel C, Troncoso MF et al. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival // Cell Mol Life Sci. — 2007. — 64, №13. — Р. 1679-700.
  33. Eriksson P, Deguchi H, Samnegard A et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease // Arterioscler Thromb Vasc Biol. — 2004. — 24, №3. — Р. 551-7.
  34. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly // Am J Kidney Dis. — 2001. — 37, №1. — Р. 79-83.
  35. Foldes G, Horkay F, Szokodi I et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure // Biochem Biophys Res Commun. — 2003. — 308, №3. — Р. 480-5.
  36. Frangogiannis NG. The immune system and cardiac repair // Pharmacol Res. — 2008. — 58, №2. — Р. 88-111.
  37. Fung JW, Yu CM, Yip G et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure // Am J Cardiol. — 2003. — 92, №4. — Р. 406-10.
  38. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques // J Clin Invest. — 1994. — 94, №6. — Р. 2493-503.
  39. Gardner RS, Ozalp F, Murday AJ et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure // Eur Heart J. — 2003. — 24, №19. — Р. 1735-43.
  40. Givertz MM, Braunwald E. Neurohormones in heart failure: predicting outcomes, optimizing care // Eur Heart J. — 2004. — 25, №4. — Р. 281-2.
  41. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N Engl J Med. — 2004. — 351, №13. — Р. 1296-305.
  42. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited // Clin Chem. — 2004. — 50, №9. — Р. 1503-10.
  43. Goto T, Takase H, Toriyama T et al. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure // Heart. — 2003. — 89, №11. — Р. 1303-7.
  44. Groenning BA, Raymond I, Hildebrandt PR et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population // Heart. — 2004. — 90, №3. — Р. 297-303.
  45. Hamada Y, Tanaka N, Murata K et al. Significance of predischarge BNP on one-year outcome in decompensated heart failure--comparative study with echo-Doppler indexes // J Card Fail. — 2005. — 11, №1. — Р. 43-9.
  46. Hansen MS, Stanton EB, Gawad Y et al. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan // Am J Cardiol. — 2002. — 90, №9. — Р. 969-73.
  47. Hartmann F, Packer M, Coats AJ et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial // Circulation. — 2004. — 110, №13. — Р. 1780-6.
  48. Hartog JW, Voors AA, Bakker SJ et al. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications // Eur J Heart Fail. — 2007. — 9, №12. — Р. 1146-55.
  49. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis // Proc Natl Acad Sci USA. — 2006. — 103, №13. — Р. 5060-5.
  50. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis // Am J Pathol. — 2008. — 172, №2. — Р. 288-98.
  51. Henn V, Slupsky JR, Gräfe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells // Nature. — 1998. — 391, №6667. — Р. 591-4.
  52. Hill JM, Dick AJ, Raman VK et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells // Circulation. — 2003. — 108, №8. — P.1009-14.
  53. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure // Circulation. — 2003. — 108, №7. — Р. 833-8.
  54. Hsu DK, Dowling CA, Jeng KC et al. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma // Int J Cancer. — 1999. — 81, №4. — Р. 519-26.
  55. Hudson MP, O’Connor CM, Gattis WA et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis // Am Heart J. — 2004. — 147, №3. — Р. 546-52.
  56. Hughes RC. The galectin family of mammalian carbohydrate-binding molecules // Biochem Soc Trans. — 1997. — 25, №4. — Р. 1194-8.
  57. Ince H, Petzsch M, Kleine HD et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI) // Circulation. 2005. — 112, №20. — P. 3097-106.
  58. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion // Cancer Res. — 1996. — 56, №19. — Р. 4530-4.
  59. Inoue T, Kato T, Takayanagi K et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome // Am J Cardiol. — 2003. — 92, №12. — P. 1461-4.
  60. Ishida J, Hashimoto T, Hashimoto Y et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo // J Biol Chem. — 2004. — 279, №25. — Р. 26274-9.
  61. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study // Circulation. — 2007. — 115, №2. — Р. 173-9.
  62. Jack DL, Klein NJ, Turner MW. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis // Immunol Rev. — 2001. — 180. — Р. 86-99.
  63. Jelkmann W. Molecular biology of erythropoietin // Intern Med. — 2004. — 43, №8. — Р. 649-59.
  64. Jugdutt BI, Joljart MJ, Khan MI. Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models // Circulation. — 1996. — 94, №1. — Р. 94-101.
  65. Kabe Y, Ando K, Hirao S et al. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus // Antioxid Redox Signal. — 2005. — 7, №3-4. — P. 395-403.
  66. Kannel WB, D’Agostino RB, Silbershatz H et al. Profile for estimating risk of heart failure // Arch Intern Med. — 1999. — 159, №11. Р. 1197-204.
  67. Kawachi K, Matsushita Y, Yonezawa S et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation // Hum Pathol. — 2000. — 31, №4. — Р. 428-33.
  68. Kawasaki T. Structure and biology of mannan-binding protein, MBP, an important component of innate immunity // Biochim Biophys Acta. — 1999. — 1473, №1. — Р. 186-95.
  69. Kim H, Lee J, Hyun JW et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues // Cell Biol Int. — 2007. — 31, №7. — Р. 655-62.
  70. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells // Cancer Res. — 1999. — 59, №16. — Р. 4148-54.
  71. Kinugasa Y, Ogino K, Furuse Y et al. Allopurinol improves cardiac dysfunction after ischemia-reperfusion via reduction of oxidative stress in isolated perfused rat hearts // Circ J. — 2003. — 67, №9. — P. 781-7.
  72. Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man // Mol Cell Biochem. — 1992. — 116, №1-2. — Р. 155-62.
  73. Krześlak A, Lipińska A. Galectin-3 as a multifunctional protein // Cell Mol Biol Lett. — 2004. — 9, №2. — Р. 305-28.
  74. Kuethe F, Richartz BM, Sayer HG et al. Lack of regeneration of myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans with large anterior myocardial infarctions // Int J Cardiol. — 2004. — 97, №1. — P. 123-7.
  75. Lalu MM, Pasini E, Schulze CJ et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart // Eur Heart J. — 2005. — 26, №1. — P. 27-35.
  76. Lam CS, Grewal J, Borlaug BA et al. Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity // Hypertension. — 2010. — 55, №5. — P. 1143-9.
  77. Latini R, Masson S, Anand I et al. he comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT // Eur Heart J. — 2004. — 25, №4. — Р. 292-9.
  78. Lee DS, Austin PC, Rouleau JL et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model // JAMA. — 2003. — 290, №19. — Р. 2581-7.
  79. Lee AA, Delhaas T, McCulloch AD, Villarreal FJ. Differential responses of adult cardiac fibroblasts to in vitro biaxial strain patterns // J Mol Cell Cardiol. — 1999. — 31, №10. — P. 1833-43.
  80. Lewis BS, Karkabi B, Jaffe R et al. Anaemia and heart failure: statement of the problem // Nephrol Dial Transplant. — 2005. — 20, Suppl 7. — Р. 3-6.
  81. Li L, Okada H, Takemura G et al. Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction // Am J Physiol Heart Circ Physiol. — 2009 — 297, №4. — P. 1504-13.
  82. Limas CJ, Hasikidis C, Iakovou J et al. Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy // Eur J Clin Invest. — 2003. — 33, №6. — Р. 443-8.
  83. Lin YH, Lin LY, Wu YW et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients // Clin Chim Acta. — 2009. — 409, №1-2. — Р. 96-9.
  84. Liu YH, D’Ambrosio M, Liao TD et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin // Am J Physiol Heart Circ Physiol. — 2009. — 296, №2. — Р. 404-12.
  85. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins // Biochim Biophys Acta. — 2002. — 1572, №2-3. — Р. 263-73.
  86. Lu J. Collectins: collectors of microorganisms for the innate immune system // Bioessays. — 1997. — 19, №6. — Р. 509-18.
  87. Maisel A, Hollander JE, Guss D et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath // J Am Coll Cardiol. — 2004. — 44, №6. — Р. 1328-33.
  88. Maisel AS, McCord J, Nowak RM et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study // J Am Coll Cardiol. — 2003. — 41, №11. — Р. 2010-7.
  89. Maron BJ, Tholakanahalli VN, Zenovich AG et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy // Circulation. — 2004. — 109, №8. — Р. 984-9.
  90. Matsunaga T, Abe N, Kameda K et al. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction // Int J Cardiol. — 2005. — 105, №2. — P. 203-8.
  91. Matarrese P, Fusco O, Tinari N et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties // Int J Cancer. — 2000. — 85, №4. — Р. 545-54.
  92. McDonagh TA, Holmer S, Raymond I et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies // Eur J Heart Fail. — 2004. — 6, №3. — Р. 269-73.
  93. McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction // Lancet. — 1998. — 351, №9095. — Р. 9-13.
  94. Meldrum DR, Dinarello CA, Cleveland JC Jr et al. Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism // Surgery. — 1998. — 124, №2. — P. 291-6.
  95. Mehra MR, Uber PA, Park MH et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure // J Am Coll Cardiol. — 2004. — 43, №9. — Р. 1590-5.
  96. Menon RP, Hughes RC. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex // Eur J Biochem. — 1999. — 264, №2. — Р. 569-76.
  97. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial // Eur Heart J. — 2009. — 30, №24. — P. 2978-84.
  98. Michel JB, Lattion AL, Salzmann JL et al. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction // Circ Res. — 1988. — 62, №4. — Р. 641-50.
  99. Milting H, Ellinghaus P, Seewald M et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices // J Heart Lung Transplant. — 2008. — 27, №6. — Р. 589-96.
  100. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure // Circulation. — 1997. — 96, №9. — Р. 2953-8.
  101. Miyazaki T, Karube M, Matsuzaki Y et al. Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis // J Hepatol. — 2005. — 43, №1. — P. 117-25.
  102. Mizon-Gérard F, de Groote P, Lamblin N et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction // Eur Heart J. — 2004. — 25, №8. — Р. 688-93.
  103. Mollenhauer J. Annexins: what are they good for? // Cell Mol Life Sci. — 1997. — 53, №6. — Р. 506-7.
  104. Moon SK, Cha BY, Kim CH. ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: Involvement of the ras dependent pathway // J Cell Physiol. — 2004. — 198, №3. — P. 417-27.
  105. Moran A, Katz R, Smith NL et al. Cystatin C concentration as a predictor of systolic and diastolic heart failure // J Card Fail. — 2008. — 14, №1. — Р. 19-26.
  106. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function // Am J Cardiol. — 2003. — 92, №12. — Р. 1434-8.
  107. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea // N Engl J Med. — 2004. — 350, №7. — Р. 647-54.
  108. Mukherjee R, Brinsa TA, Dowdy KB et al. Myocardial infarct expansion and matrix metalloproteinase inhibition // Circulation. — 2003. — 107, №4. — P. 618-25.
  109. Nakahara S, Oka N, Wang Y et al. Characterization of the nuclear import pathways of galectin-3 // Cancer Res. — 2006. — 66, №20. — Р. 9995-10006.
  110. Nakamura R, Egashira K, Machida Y et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation // Circulation. — 2002. — 106, №3. — P. 362-7.
  111. Nakamura M, Endo H, Nasu M et al. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population // Heart. — 2002. — 87, №2. — Р. 131-5.
  112. Ng LL, Geeranavar S, Jennings SC et al. Diagnosis of heart failure using urinary natriuretic peptides // Clin Sci (Lond). — 2004. — 106, №2. — Р. 129-33.
  113. Ng LL, Loke IW, O’Brien RJ et al. Plasma urocortin in human systolic heart failure // Clin Sci (Lond). — 2004. — 106, №4. — Р. 383-8.
  114. Nichols TC. NF-kappaB and reperfusion injury // Drug News Perspect. — 2004. — 17, №2. — P. 99-104.
  115. Nishi Y, Sano H, Kawashima T et al. Role of galectin-3 in human pulmonary fibrosis // Allergol Int. — 2007. — 56, №1. — Р. 57-65.
  116. Novitskiy G, Potter JJ, Wang L, Mezey E. Influences of reactive oxygen species and nitric oxide on hepatic fibrogenesis // Liver Int. — 2006. — 26, №10. — P. 1248-57.
  117. Ojha N, Roy S, Radtke J et al. Characterization of the structural and functional changes in the myocardium following focal ischemia-reperfusion injury // Am J Physiol Heart Circ Physiol. — 2008. — 294, №6. — P. 2435-43.
  118. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium // Nature. — 2001. — №410(6829). — P. 701-5.
  119. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? // Circulation. — 2003. — 108, №24. — Р. 2950-3.
  120. Palladini G, Campana C, Klersy C et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis // Circulation. — 2003. — 107, №19. — Р. 2440-5.
  121. Patten RD, Aronovitz MJ, Einstein M et al. Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse // Clin Sci (Lond) — 2003. — 104, 2. — Р. 109-18.
  122. Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload // Hypertension. — 2000. — 36, №3. — Р. 355-9.
  123. Perrin M, Donaldson C, Chen R et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart // Proc Natl Acad Sci U S A. — 1995. — 92, №7. — Р. 2969-73.
  124. Poulsen SH, Høst NB, Jensen SE, Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction // Circulation. — 2000. — 101, №13. — Р. 1527-32.
  125. Powell LD, Varki A. I-type lectins. J Biol Chem. — 1995. — 270, №24. — Р. 14243-6.
  126. Rademaker MT, Charles CJ, Espiner EA et al. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep // J Am Coll Cardiol. — 2002. — 40, №8. — Р. 1495-505.
  127. Rakusan K, Cicutti N, Kolar F. Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts // Am J Physiol Heart Circ Physiol. — 2001. — 280, №3. — Р. 1407-14.
  128. Raz A, Lotan R. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis // Cancer Metastasis Rev. — 1987. — 6, №3. — Р. 433-52.
  129. Raz A, Zhu DG, Hogan V et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis // Int J Cancer. — 1990. — 46, №5. — Р. 871-7.
  130. Reifenberg K, Lehr HA, Torzewski M et al. Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice // Am J Pathol. — 2007. — 171, №2. — Р. 463-72.
  131. Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? // J Am Coll Cardiol. — 2004. — 44, №4. — Р. 740-9.
  132. Rosen SD, Bertozzi CR. The selectins and their ligands // Curr Opin Cell Biol. — 1994. — 6, №5. — Р. 663-73.
  133. Ryan TD, Rothstein EC, Aban I et al. Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload // J Am Coll Cardiol. — 2007. — 49,№7. — P. 811-21.
  134. Saggiorato E, Cappia S, De Giuli P et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma // J Clin Endocrinol Metab. — 2001. — 86, №11. — Р. 5152-8.
  135. Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies // J Pathol. — 1999. — 187, №4. — Р. 481-9.
  136. Sato S, Hughes RC. Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin // J Biol Chem. — 1992. — 267, №10. — Р. 6983-90.
  137. Satо S, Hughes RC. Regulation of Secretion and Surface Expression of Mac-2, a Galactoside-binding Protein of Macrophages // J. Biol. Chem. — 1994. — 269, №6. — Р. 4424-4430.
  138. Sato Y, Yamada T, Taniguchi R et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes // Circulation. — 2001. — 103, №3. — Р. 369-74.
  139. Schieffer B, Wirger A, Meybrunn M et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat // Circulation. — 1994. — 89, №5. — Р. 2273-82.
  140. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction // Circulation. — 2004. — 110, №19. — Р. 3121-8.
  141. Shlipak MG, Wassel Fyr CL, Chertow GM et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study // J Am Soc Nephrol. — 2006. — 17, №1. — Р. 254-61.
  142. See F, Kompa A, Martin J et al. Fibrosis as a therapeutic target post-myocardial infarction // Curr Pharm Des. — 2005. — 11, №4. — P. 477-87.
  143. Setsuta K, Seino Y, Ogawa T et al. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure // Am J Med. — 2002. — 113, №9. — Р. 717-22.
  144. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function // Physiol Rev. — 2007. — 87, №4. — P. 1285-342.
  145. Strauer BE, Brehm M, Zeus T et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans // Circulation. — 2002. — 106, №15. — Р. 1913-8.
  146. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts // Am J Physiol Cell Physiol. — 2001. — 280, №1. — Р. 53-60.
  147. Sun Y, Weber KT. Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart // J Mol Cell Cardiol. — 1996. — 28, №5. — Р. 851-8.
  148. Sun Y, Weber KT. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat // J Lab Clin Med. — 1996. — 127, №1. — Р. 94-101.
  149. Sundstrom J, Evans JC, Benjamin EJ et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study // Eur Heart J. — 2004. — 25, №17. — P. 1509-16.
  150. Sundstrom J, Evans JC, Benjamin EJ et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study // Circulation. — 2004. — 109, №23. — Р. 2850-6.
  151. Szokodi I, Tavi P, Foldes G et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility // Circ Res. — 2002. — 91, №5. — Р. 434-40.
  152. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options // Circulation. — 2006. — 113, №20. — Р. 2454-61.
  153. Thandavarayan RA, Watanabe K, Ma M et al. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy // Biochem Pharmacol. — 2008. — 75, №9. — Р. 1797-806.
  154. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension // Clin Exp Pharmacol Physiol. — 2003. — 30, №11. — Р. 860-6.
  155. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects // Eur J Heart Fail. — 2004. — 6, №3. — Р. 261-8.
  156. Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death // N Engl J Med. — 2004. — 350, №7. — Р. 655-63.
  157. Wang L, Friess H, Zhu Z et al. Galectin-1 and galectin-3 in chronic pancreatitis // Lab Invest. — 2000. — 80, №8. — Р. 1233-41.
  158. Van Kimmenade RR, Januzzi JL Jr, Ellinor PT et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure // J Am Coll Cardiol. — 2006. — 48, №6. — Р. 1217-24.
  159. Van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair // Adv Immunol. — 1996. — 61. — Р. 1-77.
  160. Van Krimpen C, Smits JF, Cleutjens JP et al. DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril // J Mol Cell Cardiol. — 1991. — 23, №11. — Р. 1245-53.
  161. Vasan RS, Benjamin EJ, Larson MG et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study // JAMA. — 2002. — 288, №10. — Р. 1252-9.
  162. Vasan RS, Sullivan LM, Roubenoff R et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study // Circulation. — 2003. — 107, №11. — Р. 1486-91.
  163. Vlassara H, Li YM, Imani F et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex // Mol Med. — 1995. — 1, №6. — Р. 634-46.
  164. Webb CS, Bonnema DD, Ahmed SH et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling // Circulation. — 2006. — 114, №10. — P. 1020-7.
  165. Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair // Semin Nephrol. — 1997. — 17, №5. — Р. 467-91.
  166. Weinberg EO, Shimpo M, Hurwitz S et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker // Circulation. — 2003. — 107, №5. — Р. 721-6.
  167. White HD, Norris RM, Brown MA et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction // Circulation. — 1987. — 76, №1. — P. 44-51.
  168. Wojakowski W, Tendera M, Zebzda A et al. Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction // Eur Heart J. — 2006. — 27, №3. — P. 283-9.
  169. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure // Eur J Heart Fail. — 2004. — 6, 3. — Р. 355-8.
  170. Yamagishi H, Kim S, Nishikimi T et al. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats // J Mol Cell Cardiol. — 1993. — 25, №11. — Р. 1369-80.
  171. Yamamoto K, Burnett JC Jr, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart // Am J Physiol. — 1997. — 273, №5. — Р. 2406-14.
  172. Yamazaki K, Kawai A, Kawaguchi M et al. Simultaneous induction of galectin-3 phosphorylated on tyrosine residue, p21(WAF1/Cip1/Sdi1), and the proliferating cell nuclear antigen at a distinctive period of repair of hepatocytes injured by CCl4 // Biochem Biophys Res Commun. — 2001. — 280, №4. — Р. 1077-84.
  173. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis // Proc Natl Acad Sci U S A. — 1996. — 93, №13. — Р. 6737-42.
  174. Yin WH, Chen JW, Jen HL et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure // Eur J Heart Fail. — 2003. — 5, №4. — Р. 507-16.
  175. Yousef M, Schannwell CM, Köstering M et al. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction // J Am Coll Cardiol. — 2009. — 53, №24. — P. 2262-9.

Перейти до змісту На початок Версія для друку